Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 2,515 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Metabolic Disease, Obesity, Li-Fraumeni Syndrome, Cardiomyopathy, Atherosclerosis, Inflammatory Disease
Interventions: NSR IDE-MRI: Research pulse sequences; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 1 Year to 100 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Contact Lens Solutions
Interventions: Solution 1 (Test), Solution 2 (Test), Solution 3 (Test), Solution 4 (Control); Other
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 269 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: LY3410738, Itraconazole, Carbamazepine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Presbyopia
Interventions: etafilcon A, lotrafilcon B; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 298 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 19
States / cities: Mission Viejo, California • Jacksonville, Florida • Saint Augustine, Florida + 15 more

Conditions: Acute Liver Failure, Fulminant Hepatic Failure
Interventions: N-acetylcysteine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 15 more

Conditions: Healthy Control
Interventions: Swedish Massage Therapy, Light Touch Control; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 64 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cocaine Use Disorder
Interventions: Original formulation EMB-001, New formulation EMB-001; Drug
Lead sponsor: Embera NeuroTherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Migraine, Small Vessel Ischemic Disease, Multiple Sclerosis
Interventions: Brain Neuroimaging; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 59 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: Midazolam, AIN457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 5 more

Conditions: Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer
Interventions: Comparative Genomic Hybridization, Laboratory Biomarker Analysis, Polymerase Chain Reaction; Genetic · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Muskuloskeletal Diseases, Healthy, Respiratory
Interventions: MRI; Diagnostic Test
Lead sponsor: Laura Walkup; Other
Eligibility: 5 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cystic Fibrosis
Interventions: VNZ/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Renal Cancer
Interventions: Magnetic Resonance Imaging (MRI) Scan, Tc-99m Pentetate; Device · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 85 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions: 3-Tesla magnetic resonance imaging, CEST-MRI, DW-MRI, DCE-MRI, DSC-MRI, IV administration of gadolinium-containing contrast agent; Device · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Interventions: Ibrutinib, Copanlisib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Healthy Volunteers
Interventions: Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Amyloidosis
Interventions: Magnetic Resonance Elastography (MRE); Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: Brensocatib; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Melasma
Interventions: Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Healthy
Interventions: LY4100511 (DC-853), Itraconazole, Fluconazole, Carbamazepine; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Metastatic Colorectal Cancer
Interventions: Fruquintinib, Dabigatran Etexilate, Rosuvastatin; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Sickle Cell Disease
Interventions: Music Therapy, Standard of Care; Other
Lead sponsor: Emory University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diffuse Apneic Oxygenation
Interventions: Oxygen, Standard of care; Other
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Spinal Cord Injury/Disorder
Interventions: Compare two control methods for a wheelchair-mounted robotic manipulator; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Clinical and Laboratory Evaluation of 3 Contact Lenses With 4 Contact Lens Solutions

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

Evaluation of the Performance of Investigational Contact Lenses in a Presbyopic Population

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

Massage: Neuroimaging and Correlates of Response - 6-week Study

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

A Study to Evaluate White Matter Hyperintensities in Migraine

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

Research Study in Patients With Advanced Ovarian Epithelial Cancer

Proton MRI of MSK Disorders

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Advanced Diffusion Imaging in Renal Cancer Patients

3T MRI Biomarkers of Glioma Treatment Response

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

Fruquintinib DDI Study With P-gp and BCRP Substrates

Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing

EmergeNcy Department Apneic Oxygenation Versus Usual Care During Rapid Sequence Intubation

Evaluation of Vision-Guided Shared Control for Assistive Robotics Manipulators